Avalon GloboCare Updates FDA Registration for KetoAir Device
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 21 Jan 26
Source: Benzinga
Avalon GloboCare's stock fell 11.09% as it crossed below its 5-day SMA, reflecting bearish momentum amid broader market gains.
The company announced the renewal of FDA establishment registration for its KetoAir device, a handheld breathalyzer aimed at ketogenic health management. This device enhances users' ability to monitor fat metabolism effectively. Avalon plans to initiate marketing efforts for KetoAir in Q2 2026, leveraging its subsidiary, Avalon Quantum AI, LLC, to expand its market presence significantly.
The implications of this FDA update could enhance Avalon GloboCare's market position, although the stock's recent performance indicates significant challenges, with a 70.51% decline over the past year.
Analyst Views on ALBT
About ALBT
Avalon GloboCare Corp. is a commercial-stage company engaged in developing and delivering precision diagnostic consumer products and the advancement of intellectual property in cellular therapy. The Company operates in two reportable business segments: the real property operating segment and the laboratory testing services segment. Its laboratory services offer a test menu that satisfies the clients' testing needs, from general bloodwork to anatomic pathology, urine toxicology, pharmacogenomics (PGx) testing and more, and it is a one-stop-shop for clinical testing. The Company is currently marketing the KetoAir breathalyzer device and plans to develop additional diagnostic uses of the breathalyzer technology. The KetoAir breathalyzer is a handheld device that allows the user to detect acetone levels in exhaled breath. The acetone level is in concentration units part-per-million (ppm) such that the user knows the real-time ketosis status.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
